FrancophonIA/ELRC3.0 huggingface dataset:
English: Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
Croatian: OD LIJEKA, AKO JE POTREBNO Neiskorišteni lijek ili otpadni materijal valja zbrinuti sukladno lokalnim propisima.
English: • Take 6 capsules in the morning then 6 capsules in the evening.
Croatian: • Uzmite 6 kapsula ujutro te 6 kapsula navečer.
English: Each carton contains either 50 or 150 film-coated tablets.
Croatian: Jedna kutija sadrži 50 ili 150 filmom obloženih tableta
English: Male patients of reproductive potential should be made aware of and discuss the potential risk of fathering a child with a qualified health-care professional.
Croatian: Muške bolesnike reproduktivne dobi kvalificirani zdravstveni radnik treba upoznati i s njima razgovarati o mogućim rizicima povezanima sa začećem djeteta.
English: Sepsis, gastrointestinal candidiasis, urinary tract infection, herpes simplex, herpes zoster Common Pneumonia, influenza, respiratory tract infection, respiratory moniliasis, gastrointestinal infection, candidiasis, gastroenteritis, infection, bronchitis, pharyngitis, sinusitis, fungal skin infection, skin candida, vaginal candidiasis, rhinitis
Croatian: Infekcije i infestacije vrlo često sepsa, gastrointestinalna kandidijaza, infekcija mokraćnih puteva, herpes simpleks, herpes zoster često upala pluća, gripa, respiratorne infekcije, respiratorna monilijaza, gastrointestinalna infekcija, kandidijaza, gastroenteritis, infekcija, bronhitis, faringitis, sinusitis, gljivična infekcija kože, kožna kandidijaza, vaginalna kandidijaza, rinitis
English: Because mycophenolate mofetil has demonstrated teratogenic effects in rats and rabbits, Myclausen capsules should not be opened or crushed to avoid inhalation or direct contact with skin or mucous membranes of the powder contained in Myclausen capsules.
Croatian: Mjere opreza koje treba poduzeti prije rukovanja lijekom ili njegove primjene Budući da je mofetilmikofenolat pokazao teratogene učinke kod štakora i kunića, Myclausen kapsule ne smiju se otvarati ni drobiti, kako bi se izbjeglo udisanje ili izravan kontakt kože ili sluznica s praškom sadržanim u Myclausen kapsulama.
English: When comparing rates of transplant rejection or rates of graft loss between mycophenolate mofetil patients taking PPIs versus mycophenolate mofetil patients not taking PPIs, no significant differences were seen.
Croatian: Uspoređujući stope odbacivanja transplantata ili stope gubitka presatka između bolesnika koji su uzimali Myclausen i IPP naspram bolesnika koji s lijekom Myclausen nisu uzimali IPP, nisu primijećene značajne razlike.
English: Cases of pure red cell aplasia (PRCA) have been reported in patients treated with mycophenolate mofetil (see section 4.4).
Croatian: Prijavljeni su slučajevi izolirane aplazije eritrocita (PRCA) kod bolesnika liječenih mofetilmikofenolatom (vidjeti dio 4.4).
English: The pharmacokinetics and pharmacodynamics of oral contraceptives were unaffected by coadministration of mycophenolate mofetil (see also section 5.2).
Croatian: Farmakokinetika i farmakodinamika oralnih kontraceptiva nije se izmijenila njihovom istodobnom primjenom s mofetilmikofenolatom (vidjeti i dio 5.2).
English: Liver transplant
Croatian: Presađivanje jetre
English: Congenital malformations, including reports of multiple malformations, have been observed postmarketing in children of patients exposed to Myclausen in combination with other immunosuppressants during pregnancy.
Croatian: Nakon stavljanja lijeka u promet prijavljene su kongenitalne malformacije, uključujući višestruke malformacije, kod djece bolesnica koje su bile izložene lijeku Myclausen u kombinaciji s drugim imunosupresivima tijekom trudnoće.
English: Concomitant administration of telmisartan and mycophenolate mofetil esulted in an approximately 30 % decrease of MPA concentrations.
Croatian: Istodobna primjena telmisartana i mofetilmikofenolata i snizila je koncentracije MPA za približno 30%.
English: The risk/benefit ratio of mycophenolate mofetil in combination with tacrolimus or sirolimus has not been established (see also section 4.5).
Croatian: Omjer rizika i koristi primjene mofetilmikofenolata u kombinaciji s takrolimusom ili sirolimusom nije ustanovljena (vidjeti i dio 4.5).
English: CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30 50 % in renal transplant patients treated with mycophenolate mofetil and CsA compared with patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section 4.4).
Croatian: A smanjuje izloženost MPA-u za 30-50% u usporedbi s bolesnicima koji primaju sirolimus ili belatacept i slične doze mofetilmikofenolata i (vidjeti i dio 4.4).
English: Mycophenolate is a powerful human teratogen.
Croatian: Mikofenolat ima snažan teratogen učinak u ljudi.
English: Therefore women of childbearing potential must use at least one form of reliable contraception (see section 4.3) before starting Myclausen therapy, during therapy, and for six weeks after stopping the therapy, unless abstinence is the chosen method of contraception.
Croatian: Stoga žene reproduktivne dobi moraju prije započinjanja liječenja, tijekom liječenja i još šest tjedana nakon prekida liječenja lijekom Myclausen koristiti najmanje jedan pouzdan oblik kontracepcije (vidjeti dio 4.3), osim ako je kao metoda kontracepcije odabrana apstinencija.
English: Isolated cases of abnormal neutrophil morphology, including the acquired Pelger-Huet anomaly, have been observed in patients treated with mycophenolate mofetil.
Croatian: Zapaženi su izolirani slučajevi patološke morfologije neutrofila, uključujući i stečenu Pelger-Huet anomaliju kod bolesnika liječenih mofetilmikofenolatom.
English: Myclausen film-coated tablets should only be prescribed to patients with a body surface area greater than 1.5 m2, at a dose of 1 g twice daily (2 g daily dose).
Croatian: Myclausen filmom obložene tablete propisuju se samo bolesnicima tjelesne površine veće od 1,5 m u dozi od 1 g dvaput dnevno (dnevna doza 2 g).
English: Note: 501 (2 g mycophenolate mofetil daily), 289 (3 g mycophenolate mofetil daily) and 277 (2 g intravenous / 3 g oral mycophenolate mofetil daily) patients were treated in Phase III studies for the prevention of rejection in renal, cardiac and hepatic transplantation, respectively.
Croatian: Napomena: u fazi III ispitivanja sprječavanja odbacivanja bubrežnog, srčanog odnosno jetrenog presatka liječeno je 501 (2 g mofetilmikofenolata dnevno), 289 (3 g mofetilmikofenolata dnevno) odnosno 277 (2 g intravenskog / 3 g oralnog mofetilmikofenolata dnevno) bolesnika.
English: MPA AUC values across age groups were similar in the early and late posttransplant period.
Croatian: Vrijednosti AUC-a MPA u ranom su i kasnom razdoblju nakon presađivanja bile slične u svim dobnim skupinama.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/10/647/003 (100 hard capsules)
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/10/647/003 (100 tvrdih kapsula)
English: Additional adverse reactions reported during post-marketing are described below with the frequencies reported within brackets if known.
Croatian: Dodatne nuspojave prijavljene u sklopu stalnog praćenja sigurnosti primjene lijeka navedene su u nastavku s učestalošću navedenom u zagradama ako je ona poznata.
English: • Advice that patients should not donate blood during therapy or for at least 6 weeks following discontinuation of mycophenolate.
Croatian: Savjet o tome da bolesnici ne smiju darivati krv tijekom liječenja ili najmanje 6 tjedana nakon prekida primjene mikofenolata.
English: The highest dose tested in the animal carcinogenicity studies resulted in approximately 2-3 times the systemic exposure (AUC or Cmax) observed in renal transplant patients at the recommended clinical dose of 2 g/day and 1.3-2 times the systemic exposure (AUC or Cmax) observed in cardiac transplant patients at the recommended clinical dose of 3 g/day.
Croatian: Najveća doza primijenjena u ispitivanjima karcinogenosti na životinjama rezultirala je 2-3 puta većom sistemskom izloženošću (AUC ili Cmax) od primijećene kod bolesnika s presađenim bubregom pri preporučenoj kliničkoj dozi od 2 g/dan te 1,3-2 puta većom sistemskom izloženošću (AUC ili Cmax) od primijećene kod bolesnika s presađenim srcem pri preporučenoj kliničkoj dozi od 3 g/dan.
English: Cases of spontaneous abortions have been reported in patients exposed to mycophenolate mofetil, mainly in the first trimester, see section 4.6.
Croatian: U bolesnica izloženih mofetilmikofenolatu prijavljeni su slučajevi spontanog pobačaja, prvenstveno u prvom tromjesečju trudnoće (vidjeti dio 4.6).
English: Mean plasma MPAG AUC (0-12 h) was 2-3-fold higher than in post-transplant patients without delayed graft function.
Croatian: Srednji AUC (0-12 h) MPAG-a u plazmi bio je 2-3 puta veći nego kod bolesnika kod kojih nakon presađivanja nije došlo do odgođene funkcije presatka.
English: • Your doctor will decide the most appropriate dose based on your child's height and weight
Croatian: • Liječnik će odrediti odgovarajuću dozu na temelju visine i težine Vašeg djeteta (tjelesna površina mjerena u metrima kvadratnim ili “ m2”).
English: Men must not donate semen during treatment with Myclausen and for at least 90 days after stopping treatment.
Croatian: Muškarci ne smiju donirati spermu tijekom liječenja lijekom Myclausen i najmanje 90 dana nakon prestanka liječenja.
English: Grounds for the variation to the terms of the marketing authorisation(s) On the basis of the scientific conclusions for mycophenolate mofetil, mycophenolic acid the CHMP is of the opinion that the benefit-risk balance of the medicinal product(s) containing mycophenolate mofetil, mycophenolic acid is unchanged subject to the proposed changes to the product information
Croatian: Na temelju znanstvenih zaključaka za mofetilmikofenolat / mikofenolatnu kiselinu, CHMP smatra da je omjer koristi i rizika lijeka(ova) koji sadrži(e) mofetilmikofenolat / mikofenolatnu kiselinu nepromijenjen, uz predložene izmjene informacija o lijeku.
English: Patients receiving immunosuppressive regimens involving combinations of medicinal products, including Myclausen, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.8).
Croatian: Bolesnici koji primaju imunosupresivnu terapiju koja obuhvaća kombinaciju lijekova, uključujući i Myclausen, izloženi su povećanom riziku od nastajanja limfoma i drugih zloćudnih bolesti, osobito kože (vidjeti dio 4.8).
English: • inflammation of the pancreas, colon or stomach
Croatian: • upala gušterače, crijeva ili želuca
English: • fluid on the lungs or inside the chest
Croatian: • tekućina u plućnoj ili prsnoj šupljini
English: A minor acylglucuronide (AcMPAG) is also formed.
Croatian: Nastaje i sporedan metabolit, acilglukuronid (AcMPAG).
English: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially ‘sodium-free'.
Croatian: Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po dozi, tj. zanemarive kolicine natrija.
English: Tablet coat: Polyvinyl alcohol (partially hydrolysed), titanium dioxide (E 171) macrogol 3000,talc
Croatian: Polivinilni alkohol (djelomično hidroliziran), titanijev dioksid (E 171), makrogol 3000, talk Kako Myclausen izgleda i sadržaj pakiranja
English: Urinary problems such as: • kidney problems or the urgent need to pass water (urine).
Croatian: Poteškoće s mokrenjem kao što su: • poteškoće s bubrezima ili hitna potreba za mokrenjem.
English: Mycophenolate causes birth defects and miscarriage.
Croatian: Mikofenolat uzrokuje prirođene mane i spontani pobačaj.
English: Elderly patients may be at an increased risk of adverse events such as certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared with younger individuals (see section 4.8).
Croatian: U usporedbi s mlađim osobama, kod starijih bolesnika može postojati povećan rizik od štetnih događaja, kao što su određene infekcije (uključujući tkivno invazivnu citomegalovirusnu bolest), a potencijalno i gastrointestinalno krvarenje te plućni edem (vidjeti dio 4.8).
English: In vivo, MPAG is converted back to free MPA via enterohepatic recirculation.
Croatian: In vivo, MPAG se enterohepatičnom recirkulacijom ponovno pretvara u slobodni MPA.
English: NAME OF THE MEDICINAL PRODUCT Myclausen 500 mg film-coated tablets
Croatian: NAZIV LIJEKA Myclausen 500 mg filmom obložene tablete
English: In hepatic transplant patients initiated on mycophenolate mofetil and tacrolimus, the AUC and Cmax of MPA, the active metabolite of mycophenolate mofetil, were not significantly affected by coadministration with tacrolimus.
Croatian: Kod bolesnika s presađenom jetrom kod kojih je započeto liječenje mofetilmikofenolatom i takrolimusom, istodobna primjena takrolimusa nije značajno utjecala na AUC i Cmax aktivnog metabolita mofetilmikofenolata, MPA.
English: Pharmacokinetic parameters were evaluated in 49 paediatric renal transplant patients (aged 2 to 18 years) given 600 mg/m mycophenolate mofetil orally twice daily.
Croatian: Farmakokinetički parametri ispitani su kod 49 pedijatrijskih bolesnika s bubrežnim presatkom (u dobi od 2 do 18 godina) koji su dvaput dnevno peroralno primali 600 mg/m mofetilmikofenolata.
English: Children • There is no information for the use of Myclausen in children with a heart transplant.
Croatian: Djec • Nema podataka o primjeni lijeka Myclausen kod djece s presađenim srcem.
English: Hypogammaglobulinaemia has been reported in patients receiving mycophenolate mofetil in combination with other immunosuppressants (frequency not known).
Croatian: Prijavljena je hipogamaglobulinemija kod bolesnika koji primaju mofetilmikofenolat u kombinaciji s drugim imunosupresivima (učestalost nepoznata).
English: Patients should not donate blood during therapy or for at least 6 weeks following discontinuation of mycophenolate.
Croatian: Bolesnici ne smiju darivati krv tijekom liječenja ili najmanje 6 tjedana nakon prekida primjene mikofenolata.
English: Skin problems such as • acne, cold sores, shingles, skin growth, hair loss, rash, itching.
Croatian: Probleme s kožom kao što su: • akne, groznice, herpes zoster, kožne izrasline, gubitak kose, osip, svrbež.
English: Patients receiving immunosuppressive regimens involving combinations of medicinal products, including mycophenolate mofetil, are at increased risk of developing lymphomas and other malignancies, particularly of the skin (see section 4.4).
Croatian: Bolesnici koji primaju imunosupresivnu terapiju koja obuhvaća kombinaciju lijekova, uz ostalo i mofetilmikofenolat, izloženi su povećanom riziku od nastajanja limfoma i drugih zloćudnih bolesti, osobito kože (vidjeti dio 4.4).
English: NAME OF THE MARKETING AUTHORISATION HOLDER Passauer Pharma GmbH
Croatian: NAZIV NOSITELJA ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET Passauer Pharma GmbH
English: How to store Myclausen
Croatian: Kako čuvati Myclausen
English: Elderly patients receiving mycophenolate mofetil as part of a combination immunosuppressive regimen, may be at increased risk of certain infections (including cytomegalovirus tissue invasive disease) and possibly gastrointestinal haemorrhage and pulmonary oedema, compared to younger individuals.
Croatian: Starije osobe koje primaju mofetilmikofenolat kao dio kombiniranog imunosupresivnog liječenja mogu u odnosu na mlađe pojedince biti izložene povećanom riziku od određenih infekcija (uključujući invazivnu citomegalovirusnu bolest), a vjerojatno i gastrointestinalnih krvarenja te plućnog edema.
English: Children • There is no information for the use of Myclausen in children with a liver transplant.
Croatian: Djeca • Nema podataka o primjeni lijeka Myclausen kod djece s presađenom jetrom.
English: NAME OF THE MEDICINAL PRODUCT Myclausen 250 mg hard capsules
Croatian: NAZIV LIJEKA Myclausen 250 mg tvrde kapsule
English: Ciprofloxacin and amoxicillin plus clavulanic acid Reductions in pre-dose (trough) MPA concentrations of about 50 % have been reported in renal transplant recipients in the days immediately following commencement of oral ciprofloxacin or amoxicillin plus clavulanic acid.
Croatian: Ciprofloksacin i amoksicilin s klavulanskom kiselinom Odmah nakon početka primjene oralnog ciprofloksacina i klavulanske kiseline uočena su, kod primatelja bubrežnog presatka, smanjenja najnižih koncentracija mikofenolatne kiseline (izmjerena neposredno prije primjene sljedeće doze lijeka) na oko 50 % . Ovaj učinak se smanjuje daljnjom primjenom antibiotika i prestaje unutar nekoliko dana od prekida primjene antibiotika.
English: • If you are a woman who could be pregnant and you have not provided a negative pregnancy test before your first prescription, as mycophenolate causes birth defects and miscarriage.
Croatian: • ako ste žena koja bi mogla zatrudnjeti, a niste predočili negativan nalaz testa na trudnoću prije nego što
English: • Background information on mycophenolate mofetil teratogenicity and mutagenicity in humans.
Croatian: Pozadinske informacije o teratogenosti i mutagenosti mofetilmikofenolata u ljudi.
English: In patients with delayed renal graft function post-transplant, mean MPA AUC (0-12 h) was comparable to that seen in post-transplant patients without delayed graft function.
Croatian: Kod bolesnika kod kojih nakon presađivanja dolazi do odgođene funkcije presađenog bubrega srednji AUC (0-12 h) MPA mogao se usporediti s AUC-om MPA bolesnika kod kojih nakon presađivanja nije došlo do odgođene funkcije presađenog bubrega.
English: The systemic exposure at these levels is approximately equivalent to or less than 0.5 times the clinical exposure at the recommended clinical dose of 2 g/day for renal transplant patients and approximately 0.3 times the clinical exposure at the recommended clinical dose of 3 g/day for cardiac transplant patients (see section 4.6).
Croatian: Sistemska izloženost na tim razinama otprilike je ekvivalentna ili manja od 0,5 puta od kliničke izloženosti pri preporučenoj kliničkoj dozi od 2 g/dan za bolesnike s presađenim bubregom i otprilike 0,3 puta od kliničke izloženosti pri preporučenoj kliničkoj dozi od 3 g/dan kod bolesnika s presađenim srcem (vidjeti dio 4.6).
English: The available evidence does not indicate an increased risk of malformations or miscarriage if the father takes mycophenolate.
Croatian: Kontracepcija u muškaraca koji uzimaju Myclausen Dostupni dokazi ne ukazuju na povećan rizik od malformacija ili spontanog pobačaja ako otac uzima mikofenolat.
English: Spontaneous abortion (rate of 45% to 49%) and congenital malformations (estimated rate of 23% to 27%) have been reported following MMF exposure during pregnancy.
Croatian: Nakon izlaganja mofetilmikofenolatu tijekom trudnoće prijavljeni su spontani pobačaj (stopa: 45 - 49%) i kongenitalne malformacije (procijenjena stopa: 23 - 27%).
English: No pharmacokinetic data are available during hepatic transplant rejection.
Croatian: Farmakokinetički podaci za slučaj reakcije odbacivanja presađene jetre nisu dostupni.
English: Bile acid sequestrants, such as cholestyramine, can remove MPA by decreasing the enterohepatic recirculation of the drug (see section 5.2).
Croatian: Lijekovi za snižavanje razine žučnih kiselina, npr. kolestiramin, mogu ukloniti MPA smanjivanjem enterohepatične recirkulacije lijeka (vidjeti dio 5.2).
English: Adverse reactions, probably or possibly related to mycophenolate mofetil, reported in ≥ 1/10 and in ≥ 1/100 to < 1/10 of patients treated with mycophenolate mofetil in the controlled clinical trials of renal (2 g data), cardiac and hepatic transplant patients are listed in the following table.
Croatian: Nuspojave, vjerojatno ili moguće povezane s mofetilmikofenolatom, prijavljene u kontroliranim kliničkim ispitivanjima bolesnika s presađenim bubregom (podaci za dozu od 2 g), srcem ili jetrom kod ≥ 1/10 i ≥ 1/100 do < 1/10 bolesnika liječenih mofetilmikofenolatom, navedene su u sljedećoj tablici.
English: Use in cardiac transplant
Croatian: Primjena kod presađivanja srca
English: There may be a transient increase in the free fraction and concentration of plasma MPA in patients with delayed renal graft function.
Croatian: Kod bolesnika s odgođenom funkcijom presatka može doći do kratkotrajnog povećanja slobodnog udjela i koncentracije MPA u plazmi.
English: Pregnancy, puerperium and perinatal conditions
Croatian: Stanja vezana uz trudnoću, babinje i perinatalno razdoblje
English: Trimethoprim/sulfamethoxazole No effect on the bioavailability of MPA was observed.
Croatian: Nije primijećen utjecaj na biorasploživost MPA.
English: Ciclosporin A (CsA) pharmacokinetics are unaffected by mycophenolate mofetil.
Croatian: Mofetilmikofenolat ne utječe na farmakokinetiku ciklosporina A.
English: This includes: Before you start taking Myclausen During your entire treatment with Myclausen For 6 weeks after you stop taking Myclausen.
Croatian: • razdoblje od 6 tjedana nakon što prestanete uzimati Myclausen.
English: • sinus problems.
Croatian: • poteškoće sa sinusima.
English: The pharmacokinetics of oral contraceptives were unaffected by coadministration of mycophenolate mofetil (see also section 4.5).
Croatian: Farmakokinetika oralnih kontraceptiva nije se izmijenila njihovom istodobnom primjenom s mofetilmikofenolatom (vidjeti i dio 4.5).
English: Furthermore, men should not donate semen during therapy or for 90 days following discontinuation of mycophenolate.
Croatian: Osim toga, muškarci ne smiju donirati spermu tijekom liječenja ili 90 dana nakon prekida primjene mikofenolata.
English: Microcrystalline cellulose Povidone (K-30) Croscarmellose sodium Magnesium stearate
Croatian: Jezgra tablete Mikrokristalična celuloza Povidon (K-30) Umrežena karmelozanatrij Magnezijev stearat
English: There have been reports of hypogammaglobulinaemia in association with recurrent infections in patients receiving mycophenolate mofetil in combination with other immunosuppressants.
Croatian: Prijavljeni su slučajevi hipogamaglobulinemije povezani s rekurentnim infekcijama kod bolesnika koji su primali Mofetilmikofenolata u kombinaciji s drugim imunosupresivima.
English: The mechanism for mycophenolate mofetil induced PRCA is unknown.
Croatian: Način na koji mofetilmikofenolat uzrokuje izoliranu aplaziju eritrocita nije poznat.
English: No data are available for cardiac transplant patients with severe hepatic parenchymal disease.
Croatian: Nisu dostupni podaci za bolesnike s presađenim srcem i teškim oštećenjem jetrenog parenhima.
English: Common Hepatitis, jaundice, hyperbilirubinaemia
Croatian: Poremećaji jetre i žuči vrlo čestočesto hepatitis, žutica, hiperbilirubinemija
English: Therefore, a change in the dose of Myclausen should not normally be necessary in the absence of clinical evidence of graft dysfunction.
Croatian: Stoga, u odsutnosti kliničkih dokaza disfunkcije presatka, promjena doze Myclausena obično nije potrebna.
English: • swelling of the gums and mouth ulcers
Croatian: • oticanje desni i ulkusi u ustima
English: No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
Croatian: Prilagodbe doze nisu potrebne kod bolesnika s presađenim bubregom i teškim oštećenjem jetrenog parenhima.
English: You are a woman who is not capable of becoming pregnant if any of the following applies to you:
Croatian: U slučaju da se bilo koji od sljedećih navoda odnosi na Vas, Vi ste žena koja ne može zatrudnjeti:
English: Myclausen 500 mg film-coated tablets Mycophenolate mofetil
Croatian: Myclausen 500 mg filmom obložene tablete mofetilmikofenolat
English: In contrast, there was an increase of approximately 20 % in tacrolimus AUC when multiple doses of mycophenolate mofetil (1.5 g BID) were administered to hepatic transplant patients taking tacrolimus.
Croatian: Nasuprot tome, kod bolesnika s presađenom jetrom koji su uzimali takrolimus, došlo je do povećanja AUC-a takrolimusa za otprilike 20 % pri uzimanju višestrukih doza mofetilmikofenolata (1,5 g dvaput dnevno).